Saving money and getting value for money have always been essential parts of life. We are now being told by governments, managers, health providers, and so on that we are living in austere times and it is vital to look to every penny for savings. So can we save money in our practice of anaesthesia, if so, how much can we save, or have we reached a limit beyond which any further savings are impossible?
A good starting point is the position that we must cut out all waste. We all know what 'waste' isconsuming a resource or item without obtaining its value or benefit. Identifying this, however, is not as easy as it might sound and defining what is wasted in the context of a complex healthcare environment even more so. It is commonplace for items of equipment to be kept immediately available in case of emergency and it would be difficult to argue against this practice. If that equipment remains wrapped and sterile, then it is not wasted as it can be returned to stock. When a drug is drawn up and not used, then it is wasted. If a surgeon cuts a piece of expensive mesh for a hernia repair down to a smaller size, there is waste, but that is inevitable as the pieces of mesh are only made in certain sizes. Ampoules of anaesthetic agents only come in certain sizes too and if less than the full contents are used, there is waste. So can we hold onto the leftovers and use them for the next patient? The answer, as is common in healthcare, is 'it depends'. If a syringe of, for example, atropine, has been drawn up in case of urgent need using a correct aseptic nontouch technique and retained unused in a clean area, then it should be safe to use for a second patient. Sharing a multidose ampoule ('double-dipping') between patients has been shown to be an unsafe practice, however. Some waste will therefore be inevitable.
Can we reduce the wastage in emergency drugs -the great majority of which are drawn up 'just in case' and then discarded? One of the main arguments for this practice is that it saves time in the event of an emergency. It is routine teaching in many resident programmes, although the practice varies widely between institutions [1] . All of my local colleagues (with a few exceptions) do this. The usual argument against this practice is that such an emergency, when a few seconds do matter is so rare that it is not necessary. But if we did not draw it up solely to save money and there was a disaster, what then? Would we like to be the patient on the table when this situation presented itself? The cost-saving equation has now developed a safety component.
One option which has been explored by some hospitals (my own included) is the use of prefilled syringes. As we have not all moved over to prefilled syringes, this is clearly not the answer. Add into the equation that prefilled syringes are expensive and have a limited shelf life, whereas atropine and suxamethonium (probably the commonest drawn up emergency drugs) are incredibly cheap perhaps this is not surprising. Anaesthesia drugs may comprise up to 10-13% of a hospital pharmacy budget (Rinehardt and Sivarajan, pp. 221-225). It must be remembered, however, that this will differ greatly between hospitals depending on the ability to negotiate bulk purchases. It will also differ between countries. Individual departments also have developed their own cost-saving policies.
Newer drugs in general are safer. A good example is the muscle relaxant family. The issue of postoperative recurarization is virtually unheard of with the newer agents. Newer drugs tend to be shorter acting and have a better recovery profileimportant in the present climate where more and more is being done as a day case or overnight stay. But newer drugs tend to be more expensive. Nobody would surely countenance a reduction in safety to save a small amount of money. So there is a limit to what we can do.
This must also be put into context. Cost-saving exercises should start with the biggest slice and look at that first -a small saving in the biggest slice will not be noticed as much as a similar saving in the smallest slice. Working on the biggest slice should make the biggest impact. Anaesthetists are not, of course, the biggest slice of the operating room budget. Furthermore, the biggest part of the anaesthesia cost is staff salaries and wages. The problem is that if we reduce staffing then we reduce safety, flexibility, and workload capacity. Nobody would wish to reduce safety.
What about new agents? There has been very little development in the area of anaesthesia now for some years. It is likely that the reasons are the economics of drug companies, the safety of anaesthesia, and the desirable properties of the present agents. We do have one new drug, sugammadex (Fuchs-Buder et al., pp. 217-220). This is a revolutionary concept in anaesthesia in which we now have an agent that directly chemically inactivates rocuronium and vecuronium. So it shaves a few minutes off the reversal time at the end of surgery. Perhaps a propofol inactivating-agent would shave a few more minutes off the time also. But is that going to be an advantage? It has been eloquently put by Tremper that a time saving of a few minutes is really irrelevant [see (Rinehardt and Sivarajan, pp. 221-225)]. You cannot just add up all of the minutes across a whole set of operating rooms because a patient cannot have a small bit of their operation done in each of a series of rooms across a whole day.
The issue of increased safety for the terrifying scenario of 'cannot intubate, cannot ventilate' remains a matter for hot debate and sugammadex has been suggested as a potential lifesaver in this scenario. But it is expensive and not appropriate to have it drawn up ready with a risk of it being wasted. How fast can an anaesthetist draw up several ampoules of sugammadex into a syringe and then administer it to a patient in a dire emergency? Perhaps we need to return to the prefilled syringe debate.
Will considering the technique that we use save some money? The technique is, generally speaking, dictated by the patient's medical condition and comorbidities or type of operation. So presumably optimizing the patient's medical condition (Snowden and Anderson, pp. 210-216) might allow us a greater choice of techniques from which we can choose the cheapest. Maybe so to some extent, but the issue of safety overrides cost. I think we would all agree that optimizing the medical condition leads to a better outcome and reduced potential for morbidity and mortality. Improving perioperative morbidity will accelerate recovery and that will lead to cost savings in other areas, for example, perhaps earlier discharge times from the hospital. This brings us to consider a slightly more holistic approach to the hospital and the issue of the interactions of the many departments within the hospital and their individual budgets. Using a slightly more expensive drug in anaesthesia might be good as it results in cost savings elsewhere which are greater than the cost of the drug. But within many institutions, it is not as simple as that. If the link is not clear, the holder of the anaesthesia budget will be taken to task for an increase in expenditure, whereas the holder of the other budget is praised for savings.
Preoperative assessment and optimization clinics are a very important development and have had a clear beneficial effect on our patients. Outcome is improved and late cancellations are avoided in many cases -a clear value for money activity. Cardiopulmonary exercise testing clinics form an essential core of this assessment strategy, and their function and benefits are well described by Stringer [2] . Stringer points out their value and how they may be used to improve outcome.
What else affects outcome? Many factors of course interact here, principal among which must be the preoperative status and medical comorbidities of the patient. But does the anaesthetic technique itself affect the outcome? Kavanagh and Buggy (pp. 185-198) examines this and lists a number of obvious and not-so-obvious factors which may affect outcome. It might seem obvious that increased oxygen in the perioperative period is beneficial and accelerates the wound-healing process. As increasing numbers of patients are managed as day cases, it is not so clear how we might manage to achieve advantage from this knowledge.
We must prevent hypoxia and hypotension, but I thought that we already did that. Should we be more aggressive and use a tighter control of parameters? Maximizing analgesia is of benefit, but what is the best way of doing this? Conflicting evidence exists concerning the benefit of regional techniques versus nonregional techniques. Why is the evidence conflicting? Perhaps it is due to the small variations in the actual technique. As one of my colleagues recently put it, 'what is wrong with just giving a really excellent and perfect general anaesthetic?' Such an anaesthetic in which everything is very tightly controlled just might be better than a regional block.
Two important ethics fields relate to organ donation and to the management of substance abuse among anaesthetists. We cannot reduce the stress of a job which functions at the sharpest end of medical practice, but we can recognize where we are and have a high index of suspicion for the appearance of problems. The issue of substance abuse has always been with us and anaesthetists are known to be at high risk. If we know how to recognize the problem and catch it early, then we have the potential to reduce the problems and better, help the doctor concerned. Then just as importantly, we must work towards facilitating rehabilitation of the individual back to work. We still have a long way to go, but there are excellent programmes for recognition, management, and rehabilitation in many countries now and we are lucky to have an insight into that in Spain (Garcia-Guasch et al., pp. 204-209).
The final issue is possibly the largest globallyorgan donation. Many countries still have an opt-in method. But should we all move to an opt-out method instead? Beloucif (pp. 199-203) argues this case very well, but of course, does not come to a different conclusion, perhaps because there is presently no simple answer.
We started in the 19th and 20th centuries with the premise that the anaesthetic was a harmless activity which facilitated surgery. This general belief was held for more than 100 years. Recent work has shown that this may not be so clear-cut, however. Information is beginning to accumulate that anaesthesia has potentially harmful elements. It is time to address the question of what we can do about it. Perhaps we need to use different drugs or exert a tighter control on all parameters (blood pressure, oxygenation, tissue perfusion, glycaemic control, etc.). But this is sure to come at a cost and we have already agreed that finance is tight. It all comes down again to money, money, money.
